{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF59",
    "query": {
      "intervention": "MF59"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF59&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T11:03:59.436Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00000868",
      "title": "A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 27,
      "start_date": null,
      "completion_date": "2000-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000868"
    },
    {
      "nct_id": "NCT03014310",
      "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avian Influenza"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "MF59",
          "type": "DRUG"
        },
        {
          "name": "Monovalent Influenza A/H5N8 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 388,
      "start_date": "2017-01-09",
      "completion_date": "2018-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014310"
    },
    {
      "nct_id": "NCT01097096",
      "title": "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CAD106",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "Up to 85 Years"
      },
      "enrollment_count": 177,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 5,
      "location_summary": "Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01097096"
    },
    {
      "nct_id": "NCT05044195",
      "title": "A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "aQIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator QIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 2044,
      "start_date": "2021-09-30",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05044195"
    },
    {
      "nct_id": "NCT00000832",
      "title": "A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": null,
      "completion_date": "1998-01",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000832"
    },
    {
      "nct_id": "NCT00000946",
      "title": "A Study to Test the Safety of Three Experimental HIV Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "HIV p24/MF59 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALVAC-HIV MN120TMG (vCP205)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALVAC-RG Rabies Glycoprotein (vCP65)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000946"
    },
    {
      "nct_id": "NCT05608005",
      "title": "Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Panblok + MF59 Dose 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Panblok + MF59 Dose 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Unadjuvanted Panblok Dose 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 581,
      "start_date": "2022-11-03",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 16,
      "location_summary": "Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Saint Augustine",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05608005"
    },
    {
      "nct_id": "NCT05874713",
      "title": "Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "Infections",
        "Respiratory Tract Infections",
        "Virus Diseases",
        "Infection Viral"
      ],
      "interventions": [
        {
          "name": "aH5N8c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N8c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N8c on Day 202",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2023-06-07",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 9,
      "location_summary": "Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Lilburn",
          "state": "Georgia"
        },
        {
          "city": "Norcross",
          "state": "Georgia"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05874713"
    },
    {
      "nct_id": "NCT05501561",
      "title": "Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1056,
      "start_date": "2022-08-25",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 47,
      "location_summary": "Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501561"
    },
    {
      "nct_id": "NCT01376726",
      "title": "Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Sub C gp140 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59C.1 Adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-07",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-09-02T11:03:59.436Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376726"
    }
  ]
}